Aligos Therapeutics (NASDAQ:ALGS) Releases Quarterly Earnings Results

Posted by on Aug 6th, 2026

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.95, FiscalAI reports. The firm had revenue of $27.78 million for the quarter, compared to analysts’ expectations of $24.68 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.

Aligos Therapeutics Trading Up 16.2%

Shares of NASDAQ:ALGS traded up $0.77 during trading on Thursday, reaching $5.51. 293,190 shares of the company traded hands, compared to its average volume of 105,386. The firm has a market capitalization of $34.11 million, a price-to-earnings ratio of -0.63 and a beta of 2.31. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69. The business’s fifty day moving average is $5.33 and its 200-day moving average is $6.43.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics during the first quarter valued at approximately $2,602,000. Marshall Wace LLP bought a new position in Aligos Therapeutics in the fourth quarter worth $2,504,000. SummitTX Capital L.P. bought a new position in Aligos Therapeutics in the fourth quarter worth $1,299,000. Verition Fund Management LLC purchased a new position in Aligos Therapeutics during the fourth quarter valued at $664,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock valued at $1,683,000 after buying an additional 31,913 shares in the last quarter. 60.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ALGS. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Lake Street Capital assumed coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.50.

Read Our Latest Research Report on Aligos Therapeutics

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.

Read More

Earnings History for Aligos Therapeutics (NASDAQ:ALGS)

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.